PT  - JOURNAL ARTICLE
AU  - Vey, N.
AU  - Chretien, AS.
AU  - Dumas, PY.
AU  - Recher, C.
AU  - Gastaud, L.
AU  - Lioure, B.
AU  - Bulabois, CE.
AU  - Pautas, C.
AU  - Marolleau, JP.
AU  - Lepretre, S.
AU  - Raffoux, E.
AU  - Thomas, X.
AU  - Hichri, Y.
AU  - Bonmati, C.
AU  - Quesnel, B.
AU  - Rousselot, P.
AU  - Jourdan, E.
AU  - Malfuson, JV.
AU  - Guillerm, G.
AU  - Bourhis, JH.
AU  - Ojeda-Uribe, M.
AU  - Hunault, M.
AU  - Ben Amara, A.
AU  - Rouvière, MS.
AU  - Boucherit, N.
AU  - André, P.
AU  - Preudhomme, C.
AU  - Dulphy, N.
AU  - Toubert, A.
AU  - Ifrah, N.
AU  - Olive, D.
AU  - Dombret, H.
TI  - Randomized Phase 2 Trial of Lirilumab as maintenance Treatment in Acute Myeloid Leukemia: Results of the EFFIKIR Trial
AID  - 10.1101/2024.08.23.24312477
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.08.23.24312477
4099  - http://medrxiv.org/content/early/2024/08/23/2024.08.23.24312477.short
4100  - http://medrxiv.org/content/early/2024/08/23/2024.08.23.24312477.full
AB  - Lirilumab is a fully human monoclonal antibody designed to block killer inhibitory receptors (KIR), which are major immune checkpoints involved in the regulation of NK cell-mediated killing of HLA-I-expressing tumors. EFFIKIR is a multicenter randomized double-blind 3-arm placebo-controlled phase II trial with lirilumab as single-agent as maintenance therapy of elderly patients with AML in first complete remission (NCT01687387). Two dose schedules led to either continuous or intermittent KIR occupancy. 153 patients were randomized and 152 patients were treated after 3+7 induction therapy. The median follow-up was 36.6 months. Lirilumab was well tolerated, with no significant hematological toxicity. The median LFS were 17.6, 6.7 and 13.9 months in the 0.1mg/kg arm, 1mg/kg arm and placebo arm, respectively. An excess in early relapse led to early termination of treatment in the 1mg/kg arm. Extensive analysis of immune cell fate following KIR blockade evidenced a decrease of KIR+ NK cell absolute counts following KIR blockade, associated with a decrease of Bcl-2. Lirilumab also bound antigen-experienced CD8+ T cells, and induced a transient decrease of CD69 expression. Besides, lirilumab bound vδ2+ γδT cells with a high cytotoxic potential, and induced a decrease of DNAM-1 and Bcl-2, the latter being associated with a decrease of KIR+ γδT cell, and with a drastic reduction of time to relapse. Overall, the potentially deleterious effects on immune effectors may have resulted in the impairment of immune surveillance associated with an unexpected high rate of early relapse in the group of patients exposed to prolonged full KIR blockade.KEY POINTSProlonged full KIR blockade leads to potentially deleterious effects on NK cells, CD8+ T cells and vδ2+ γδT cellsCombined inhibitory effects of KIR blockade may have resulted in the impairment of immunosurveillance associated with high rate of relapseCompeting Interest StatementP.A. is an employee and a shareholder of Innate Pharma. D.O. is the co-founder and a shareholder of Imcheck therapeutics, Emergence therapeutics, and Alderaan Biotech.Clinical TrialNCT01687387Clinical Protocols https://clinicaltrials.gov/study/NCT01687387 Funding StatementNAAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study was approved by a national ethics committee (CPPRB) and registered at clinical trial.gov (NCT01687387).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript